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Abstract
Background: Full-term pregnancy (FTP) is associated with a reduced breast cancer (BC) risk over time, but women are at
increased BC risk in the immediate years following an FTP. No large prospective studies, however, have examined whether
the number and timing of pregnancies are associated with BC risk for BRCA1 and BRCA2 mutation carriers.
Methods: Using weighted and time-varying Cox proportional hazards models, we investigated whether reproductive events
are associated with BC risk for mutation carriers using a retrospective cohort (5707 BRCA1 and 3525 BRCA2 mutation carriers)
and a prospective cohort (2276 BRCA1 and 1610 BRCA2 mutation carriers), separately for each cohort and the combined pro-
spective and retrospective cohort.
Results: For BRCA1 mutation carriers, there was no overall association with parity compared with nulliparity (combined
hazard ratio [HRc]¼0.99, 95% confidence interval [CI]¼0.83 to 1.18). Relative to being uniparous, an increased number of FTPs
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was associated with decreased BC risk (HRc¼0.79, 95% CI¼0.69 to 0.91; HRc¼0.70, 95% CI¼0.59 to 0.82; HRc¼0.50, 95%
CI¼0.40 to 0.63, for 2, 3, and 4 FTPs, respectively, Ptrend < .0001) and increasing duration of breastfeeding was associated
with decreased BC risk (combined cohort Ptrend¼ .0003). Relative to being nulliparous, uniparous BRCA1 mutation carriers
were at increased BC risk in the prospective analysis (prospective hazard ration [HRp]¼1.69, 95% CI¼1.09 to 2.62). For BRCA2
mutation carriers, being parous was associated with a 30% increase in BC risk (HRc¼1.33, 95% CI¼1.05 to 1.69), and there
was no apparent decrease in risk associated with multiparity except for having at least 4 FTPs vs. 1 FTP (HRc¼0.72, 95%
CI¼0.54 to 0.98).
Conclusions: These findings suggest differential associations with parity between BRCA1 and BRCA2 mutation carriers with
higher risk for uniparous BRCA1 carriers and parous BRCA2 carriers.
Women carrying mutations in BRCA1 or BRCA2 are at high risk
of developing breast cancer (BC) and ovarian cancer with cumu-
lative BC risks to 80 years of 72% (95% CI¼ 65% to 79%) and 69%
(95% CI¼ 61% to 77%) for BRCA1 and BRCA2 mutation carriers,
respectively (1). For women in the general population, it is well
established that those who had their first full-term pregnancy
(FTP) at a young age (<30 years) have a lower risk of BC than nul-
liparous women or women who had their first FTP after age
30 years; additional FTPs are associated with even lower risks
(2). The consistent association between the number of pregnan-
cies and long-term reduction in BC risk is restricted to FTPs
(3–5), as incomplete pregnancies (IP) have not been associated
with BC risk [eg, (3)]. While FTPs are associated with a reduced
BC risk in the long-term, a short-term increase in BC risk has
been consistently observed for women following an FTP (6–8),
which may be reduced by breastfeeding (4,9). Thus, in addition
to being related to long-term risk reduction, breastfeeding
might mitigate a short-term increase in BC risk after FTP (10).
Given the earlier age at which BC risk increases for women
carrying a BRCA1 or BRCA2 (BRCA1/2) mutation, it is important
to know whether the BC risk for carriers is modified by the num-
ber and timing of their pregnancies and/or by breastfeeding.
However, the few studies that assessed associations with preg-
nancies and breastfeeding for BRCA1/2 mutation carriers have
reported inconsistent results [for reviews, see (11,12)], ranging
from studies supporting a decreased risk from FTP (13,14) to
studies supporting no association (15) to studies supporting an
increased risk (16). Although more limited in numbers, studies
that examined BRCA1 and BRCA2 mutation carriers separately
have supported differences in associations by mutation type
[eg, higher risk for late age at first FTP or parity in general for
BRCA2 mutation carriers (13,16) and lower risk for multiparity
for BRCA1 mutation carriers (16) and differences based on
breastfeeding (17–19)].
Most studies of BRCA1 and BRCA2 mutation carriers have
been retrospective and the few prospective studies have had
limited power to examine BRCA1 and BRCA2 mutation carriers
separately. To address these issues, we estimated BC risk asso-
ciations with reproductive history for BRCA1 and BRCA2 muta-
tion carriers separately using an international cohort comprised
of 9232 and 3886 women in the retrospective and prospective
cohorts, respectively.
Methods
Study Sample
We harmonized information from three prospective cohorts,
which included 21 national or center-based prospective follow-
up studies conducted in Western countries: the International
BRCA1/2 Carrier Cohort Study (IBCCS), the Kathleen Cuningham
Foundation Consortium for Research into Familial Breast
Cancer (kConFab) Follow-Up Study, and the Breast Cancer
Family Registry (BCFR) (20–24). Of the study participants, 84%
were enrolled through one of the five major studies: (1)
Epidemiological Study of Familial Breast Cancer (EMBRACE) in
the United Kingdom and Ireland; (2) Gene Etude Prospective
Sein Ovaire (GENEPSO) in France; (3) Hereditary Breast and
Ovarian cancer study Netherlands (HEBON) in the Netherlands;
(4) kConFab in Australia and New Zealand; and (5) BCFR in
North America and Australia.
Study Participants
Women were eligible if they were 18–80 years of age and had a
known pathogenic BRCA1 or BRCA2 mutation. Of the cohort par-
ticipants, 94% were tested in family clinics and 6% were tested
in a research setting, and it was unknown whether or when
they opted for a clinical test. We defined two subcohorts for the
analyses: (1) a prospective cohort comprising women unaffected
with BC at baseline, for whom reproductive history data from
baseline and, if collected, follow-up questionnaires were com-
bined (2276 BRCA1 and 1610 BRCA2 mutation carriers); and (2) a
retrospective cohort comprising both unaffected and affected
women at baseline, for whom only data from the baseline ques-
tionnaire were used (5707 BRCA1 and 3525 BRCA2 mutation car-
riers). The kConFab study women were included only in the
prospective cohort.
Data Collection
The baseline and follow-up questionnaires collected detailed
information on known or suspected risk factors for BC, includ-
ing reproductive and medical history and surgical interventions.
We collected family history of cancer either from the baseline
questionnaire or from pedigrees provided by the genetic
counselling centers. We collected information on cancer occur-
rences, which were confirmed by medical records including pa-
thology records, or through linkage to cancer registries for 92%
of all cases. The overall response to the follow-up question-
naires was 73% (1). Information on vital status was obtained
from municipal, death, or cancer registries or from relatives.
Participants provided written informed consent, and each study
was approved by a relevant research ethics committee.
Statistical Analysis
We used Cox proportional hazards regression models with age
as the timescale to calculate hazard ratios (HRs) to assess the
association between pregnancy-related variables (ie, parity,
number of FTPs, age at first FTP, number of years since last FTP,
breastfeeding history and duration of breastfeeding, incomplete
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Table 1. Characteristics of the BRCA1 mutation carriers in the retrospective and prospective cohort
Characteristic
Women with breast cancer Unaffected women
Retrospective Prospective Retrospective Prospective
(n¼ 2544) (n¼ 269) (n¼ 3163) (n¼ 2007)
No. (%) or mean (SD) No. (%) or mean (SD) No. (%) or mean (SD) No. (%) or mean (SD)
Age at start of follow-up, y — 40.6 (10.2) — 37.5 (11.8)
Age at censure, y 40.1 (8.8) 44.9 (10.3) 39.3 (11.5) 43.1 (12.3)
Year of birth
<1950 805 (31.6) 35 (13.0) 526 (16.6) 205 (10.2)
1950–1959 843 (33.1) 76 (28.3) 646 (20.4) 347 (17.3)
1960–1969 665 (26.1) 104 (38.7) 943 (29.8) 586 (29.2)
1970 231 (9.1) 54 (20.1) 1048 (33.1) 869 (43.3)
Study group
EMBRACE 746 (29.3) 41 (15.2) 814 (25.7) 432 (21.5)
GENEPSO 325 (12.8) 46 (17.1) 691 (21.8) 442 (22.0)
HEBON 339 (13.3) 40 (14.9) 463 (14.6) 202 (10.1)
kConFab — 55 (20.4) — 270 (13.5)
BCFR 456 (17.9) 50 (18.6) 433 (13.7) 277 (13.8)
Others* 678 (26.7) 37 (13.8) 762 (24.1) 384 (19.1)
No. of full-term pregnancies (FTP)
Nulliparous (no FTP) 518 (20.4) 51 (19.0) 951 (30.1) 602 (30.0)
1 470 (18.5) 43 (16.0) 481 (15.2) 295 (14.7)
2 924 (36.3) 113 (42.0) 1040 (32.9) 652 (32.5)
3 430 (16.9) 49 (18.2) 467 (14.8) 292 (14.5)
4 202 (7.9) 13 (4.8) 224 (7.1) 166 (8.3)
Age at 1st full-term pregnancy among parous, y
<20 286 (14.1) 26 (11.9) 244 (11.0) 148 (10.5)
20–24 830 (41.0) 73 (33.5) 794 (35.9) 482 (34.3)
25–29 620 (30.6) 73 (33.5) 776 (35.1) 511 (36.4)
30 290 (14.3) 46 (21.1) 398 (18.0) 264 (18.8)
Years since last full-term pregnancy
Nulliparous 518 (20.4) 51 (19.0) 951 (30.1) 602 (30.0)
1–5 540 (21.2) 43 (16.0) 665 (21.0) 291 (14.5)
6–20 1078 (42.4) 102 (37.9) 991 (31.3) 662 (33.0)
21 408 (16.0) 73 (27.1) 556 (17.6) 452 (22.5)
Breastfeeding duration among women with full-term pregnancy, mo
None 594 (29.3) 50 (22.9) 561 (25.4) 311 (22.1)
1–5 602 (29.7) 59 (27.1) 620 (28.0) 388 (27.6)
6–12 469 (23.1) 52 (23.9) 544 (24.6) 332 (23.6)
13–24 244 (12.0) 39 (17.9) 323 (14.6) 243 (17.3)
>24 116 (5.7) 17 (7.8) 159 (7.2) 130 (9.3)
FTP but stillborn 1 (0.0) 1 (0.5) 5 (0.2) 1 (0.1)
Incomplete pregnancy (IP)
No full-term pregnancy or IP 437 (17.2) 40 (14.9) 825 (26.1) 515 (25.7)
Full-term pregnancy, no IP 1373 (54.0) 141 (52.4) 1473 (46.6) 926 (46.1)
Induced abortion only 281 (11.0) 32 (11.9) 334 (10.6) 216 (10.8)
Miscarriage only 383 (15.1) 51 (19.0) 459 (14.5) 295 (14.7)
Induced abortion and miscarriage 70 (2.8) 5 (1.9) 72 (2.3) 55 (2.7)
Incomplete pregnancy relative to first full-term pregnancy
No IP 1833 (72.1) 184 (68.4) 2333 (73.8) 1458 (72.6)
Before first FTP or no FTP 359 (14.1) 46 (17.1) 461 (14.6) 330 (16.4)
After first FTP 352 (13.8) 39 (14.5) 369 (11.7) 219 (10.9)
Bilateral oophorectomy
No 2342 (92.1) 131 (48.7) 2253 (71.2) 1215 (60.5)
Yes 202 (7.9) 138 (51.3) 909 (28.7) 792 (39.5)
Missing 0 0 1 (0.0) 0
Oral contraceptive use
Never 605 (23.8) 39 (14.5) 653 (20.6) 290 (14.4)
Ever 1820 (71.5) 226 (84.0) 2352 (74.4) 1659 (82.7)
Unknown start age 69 (2.7) 1 (0.4) 104 (3.3) 6 (0.3)
Missing 50 (2.0) 3 (1.1) 54 (1.7) 52 (2.6)
(continued)
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pregnancies (IP) due to either spontaneous or induced abortion,
timing of IP relative to the first FTP and BC risk), both prospec-
tively (prospective hazard ratio [HRP]) and retrospectively (retro-
spective hazard ratio [HRR]). We conducted separate analyses
for BRCA1 and BRCA2 mutation carriers. We stratified all analy-
ses for birth cohort (<1950, 1950–1959, 1960–1969, 1970) and
for study group (EMBRACE, GENEPSO, HEBON, BCFR, kConFab,
and others combined) and used robust variance estimation to
account for the inclusion of related women. We assessed
whether the findings differed by age using attained age analy-
ses for women based on censoring at age 40 years. We counted
pregnancies that occurred at least one year before the age at
right censoring to exclude pregnancies that may have occurred
at the same time as diagnosis. We adjusted for bilateral oopho-
rectomy as a time-varying covariate in all of the primary analy-
ses and performed sensitivity analyses by including the
potential confounders use of oral contraceptives (as a time-
varying covariate), age at menarche, and family history of BC.
Retrospective Cohort Analysis
For retrospective analyses, we modeled time from birth to the
diagnosis of first primary BC (invasive or in situ), censoring indi-
viduals at the earliest of the following events: diagnosis of any
cancer, risk-reducing mastectomy (RRM), or completion of the
baseline questionnaire. All covariates were constructed as time-
varying covariates. All analyses of the retrospective cohort were
performed using the weighted regression approach described by
Antoniou et al. (25) to allow for the oversampling of affected
women; cohort members were weighted so that the observed
BC incidences in the study sample were consistent with estab-
lished BC risk estimates for BRCA1 and BRCA2 mutation carriers
(26). To evaluate potential survival bias, we also performed sen-
sitivity analyses for the retrospective cohort using only pseudo-
incident cases in which we considered only the follow-up from
5 years prior to study recruitment to age at censoring.
Prospective Cohort Analysis
For the prospective analysis, we considered follow-up from the
date of the baseline questionnaire to the date of diagnosis of
any cancer, RRM, last follow-up questionnaire, last information
from external source (eg, linkage), age 80 years, or loss to follow-
up or death, whichever came first. We included pregnancies
and breastfeeding as time-varying covariates.
Combined Cohort Analyses
We also conducted a combined analysis using both retrospec-
tive and prospective data. We modeled time from birth to the
date of diagnosis of any cancer, RRM, last follow-up question-
naire, last information from external source, age 80 years, loss
to follow-up or death, whichever came first, with time-
dependent weights as described by Antoniou et al. (25) for the
retrospective period and weights equal to one for the prospec-
tive period. Statistical analyses were performed using SAS 9.4.
Results
Tables 1 and 2 summarize the descriptive information for
BRCA1 and BRCA2 mutation carriers, respectively.
BRCA1 Mutation Carriers
For BRCA1 mutation carriers, there was no overall association of
parity compared with nulliparity (combined hazard ratio
[HRc]¼ 0.99, 95% CI¼ 0.83 to 1.18) (Table 3). Relative to being uni-
parous, multiparity was associated with decreased BC risk
(HRc¼ 0.79, 95% CI¼ 0.69 to 0.91; HRc¼ 0.70, 95% CI¼ 0.59 to 0.82;
HRc¼ 0.50, 95% CI¼ 0.40 to 0.63 for 2, 3, and 4 FTPs, respec-
tively, Ptrend < .0001). The reduced risk associated with multi-
parity was still evident after adjusting for age at FTP and other
risk factors. Each additional FTP after the first was associated
with a 16% (95% CI¼ 11% to 21%) and 26% (95% CI¼ 14% to 36%)
decreased risk in the retrospective and prospective analyses, re-
spectively. Figure 1 shows the probability of developing BC for
the prospective cohort. This decreasing risk with increasing par-
ity was evident across all birth cohorts (Supplementary Figure 1,
available online).
The increased risk from uniparity was only seen in the pro-
spective analysis (HRp¼ 1.69, 95% CI¼ 1.09 to 2.62). There was
Table 1. (continued)
Characteristic
Women with breast cancer Unaffected women
Retrospective Prospective Retrospective Prospective
(n¼ 2544) (n¼ 269) (n¼ 3163) (n¼ 2007)
No. (%) or mean (SD) No. (%) or mean (SD) No. (%) or mean (SD) No. (%) or mean (SD)
Age at menarche, y
<12 469 (18.4) 34 (12.6) 452 (14.3) 270 (13.5)
12 621 (24.4) 65 (24.2) 836 (26.4) 529 (26.4)
13 594 (23.3) 74 (27.5) 745 (23.6) 483 (24.1)
14 429 (16.9) 54 (20.1) 598 (18.9) 386 (19.2)
15 380 (14.9) 39 (14.5) 474 (15.0) 313 (15.6)
Age missing 51 (2.0) 3 (1.1) 58 (1.8) 26 (1.3)
Never had menstrual period 0 0 0 0
*Others included the following studies (at inlusion total number): Medical University of Vienna (MUV) (261), Modifier Study of Quantitative Effects on Disease
(MODSQUAD) (228), German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) (178), Lund-BRCA (160), Odense University Hospital (OUH) (105), Hospital
Clinico San Carlos (HCSC) (84), INterdisciplinary HEalth Research Internal Team BReast CAncer susceptibility (INHERIT) (66), National Institute of Oncology (NIO) (98),
International Hereditary Cancer Center (IHCC) (97), Stockholm-BRCA (71), The Spanish National Cancer Center (CNIO) (40), Milan Italy (33), Hospital Clinico San Carlos
(9), German Cancer Research Center (DKFZ) (4), Belgium (3), Dusseldorf Germany (3). EMBRACE ¼ Epidemiological Study of Familial Breast Cancer; GENEPSO ¼ Gene
Etude Prospective Sein Ovaire; HEBON ¼ Hereditary Breast and Ovarian cancer study Netherlands; kConFab ¼ Kathleen Cuningham Foundation Consortium for
Research into Familial Breast Cancer; BCFR ¼ Breast Cancer Family Registry.
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Table 2. Characteristics of the BRCA2 mutation carriers in the retrospective and prospective cohort
Characteristic
Women with breast cancer Unaffected women
Retrospective Prospective Retrospective Prospective
(n¼ 1560) (n¼ 157) (n¼ 1965) (n¼ 1453)
No. (%) or mean (SD) No. (%) or mean (SD) No. (%) or mean (SD) No. (%) or mean (SD)
Age at start, y 45.1 (10.1) 40.0 (12.6)
Age at censure, y 43.4 (9.1) 49.0 (10.3) 41.5 (12.4) 45.0 (13.0)
Year of birth
<1950 563 (36.1) 42 (26.8) 386 (19.6) 200 (13.8)
1950–1959 513 (32.9) 44 (28.0) 385 (19.6) 259 (17.8)
1960–1969 387 (24.8) 55 (35.0) 570 (29.0) 433 (29.8)
1970 97 (6.2) 16 (10.2) 624 (31.8) 561 (38.6)
Study group
EMBRACE 615 (39.4) 42 (26.8) 740 (37.7) 441 (30.4)
GENEPSO 161 (10.3) 18 (11.5) 437 (22.2) 307 (21.1)
HEBON 91 (5.8) 4 (2.5) 146 (7.4) 71 (4.9)
kConFab — 38 (24.2) — 250 (17.2)
BCFR 359 (23.0) 33 (21.0) 322 (16.4) 222 (15.3)
Others* 334 (21.4) 22 (14.0) 320 (16.3) 162 (11.1)
No. of full-term pregnancy (FTP)
Nulliparous (no FTP) 278 (17.8) 23 (14.6) 537 (27.3) 406 (27.9)
1 224 (14.4) 14 (8.9) 288 (14.7) 196 (13.5)
2 622 (39.9) 62 (39.5) 631 (32.1) 449 (30.9)
3 284 (18.2) 36 (22.9) 330 (16.8) 264 (18.2)
4 152 (9.7) 22 (14.0) 179 (9.1) 138 (9.5)
Age at 1st full-term pregnancy among parous, y
<20 154 (12.0) 11 (8.2) 173 (12.1) 113 (10.8)
20–24 503 (39.2) 57 (42.5) 550 (38.5) 386 (36.9)
25–29 408 (31.8) 36 (26.9) 451 (31.6) 347 (33.1)
30 217 (16.9) 30 (22.4) 254 (17.8) 201 (19.2)
Year since last full-term pregnancy
Nulliparous 278 (17.8) 23 (14.6) 537 (27.3) 406 (27.9)
1–5 280 (17.9) 16 (10.2) 410 (20.9) 175 (12.0)
6–20 669 (42.9) 63 (40.1) 590 (30.0) 484 (33.3)
21 333 (21.3) 55 (35.0) 428 (21.8) 388 (26.7)
Breastfeeding duration among women with full-term pregnancy
None 357 (27.8) 26 (19.4) 408 (28.6) 263 (25.1)
1–5 mo 342 (26.7) 36 (26.9) 389 (27.2) 255 (24.4)
6–12 mo 311 (24.3) 34 (25.4) 293 (20.5) 219 (20.9)
13–24 mo 186 (14.5) 18 (13.4) 220 (15.4) 186 (17.8)
>24 mo 84 (6.6) 20 (14.9) 115 (8.1) 122 (11.7)
FTP but stillborn 2 (0.2) 0 3 (0.2) 2 (0.2)
Incomplete pregnancy (IP)
No full-term pregnancy or IP 225 (14.4) 22 (14.0) 471 (24.0) 343 (23.6)
Full-term pregnancy, no IP 850 (54.5) 87 (55.4) 956 (48.7) 680 (46.8)
Induced abortion only 154 (9.9) 10 (6.4) 199 (10.1) 157 (10.8)
Miscarriage only 280 (17.9) 31 (19.7) 284 (14.5) 225 (15.5)
Induced abortion and miscarriage 51 (3.3) 7 (4.5) 55 (2.8) 48 (3.3)
Incomplete pregnancy relative to first full-term pregnancy
No IP 1087 (69.7) 110 (70.1) 1445 (73.5) 1036 (71.3)
Before first FTP or no FTP 256 (16.4) 22 (14.0) 270 (13.7) 229 (15.8)
After first FTP 217 (13.9) 25 (15.9) 250 (12.7) 188 (12.9)
Bilateral oophorectomy
No 1430 (91.7) 95 (60.5) 1522 (77.5) 959 (66.0)
Yes 130 (8.3) 62 (39.5) 443 (22.5) 494 (34.0)
Missing 0 0 0 0
Oral contraceptive use
Never 378 (24.2) 17 (10.8) 412 (21.0) 214 (14.7)
Ever 1106 (70.9) 136 (86.6) 1452 (73.9) 1201 (82.7)
Unknown start age 46 (2.9) 1 (0.6) 72 (3.7) 5 (0.3)
Missing 30 (1.9) 3 (1.9) 29 (1.5) 33 (2.3)
(continued)
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some suggestion that this association was stronger for women
who have never breastfed (HRp¼ 2.01, 95% CI¼ 1.14 to 3.55;
HRp¼ 1.64, 95% CI¼ 1.00 to 2.70 for women who did not and did
breastfeed, respectively), but these HRs were not statistically
different (Pheterogeneity ¼ .54]. The increased risk, although not
statistically significant (HRp¼ 1.41, 95% CI¼ 0.94 to 2.10), for
overall parity in the prospective cohort was driven mainly by
the difference in nulliparity vs uniparity between the two analy-
ses (HRp¼ 0.59, 95% CI¼ 0.38 to 0.92, and HRR¼ 1.02, 95%
CI¼ 0.83 to 1.24, respectively) because the point estimates of
each successive pregnancy compared with uniparity were simi-
lar in both the retrospective and prospective analyses.
Supplementary Figure 2 (available online) illustrates the differ-
ence based on penetrance for BRCA1 mutation carriers accord-
ing to different reproductive life scenarios.
Relative to a recent pregnancy, longer time since last FTP
was associated with higher risk in the retrospective analysis.
Increasing duration of breastfeeding was associated with de-
creased BC risk (combined cohort Ptrend¼ .0003) in the retrospec-
tive analysis (Ptrend¼ .0002), but not in the prospective analysis
(Ptrend¼ .28).
IP was associated with an increased BC risk compared with
women without IP or FTP in the prospective analysis
(HRp¼ 1.72, 95% CI¼ 1.04 to 2.83 and HRp¼ 1.77, 95% CI¼ 1.09 to
2.87 for induced abortion only and miscarriage only, respec-
tively), but not in the retrospective analysis (HRR¼ 1.02, 95%
CI¼ 0.82 to 1.27 and HRR¼ 0.97, 95% CI¼ 0.78 to 1.21 for induced
abortion only and miscarriage only, respectively). The magni-
tude of the association with IP was similar to the association for
any FTP without IP (HRp¼ 1.64, 95% CI¼ 1.03 to 2.61). There was
also no difference in association whether the IP was before or
after the first FTP in all of the analyses.
BRCA2 Mutation Carriers
For BRCA2 mutation carriers, parity was associated with a 30%
increase in BC risk (HRc¼ 1.33, 95% CI¼ 1.05 to 1.69) (Table 4).
Multiparity was associated with a decreased BC risk (HRc¼ 0.72,
95% CI¼ 0.54 to 0.98 for  4 vs 1 FTP) in the retrospective analy-
sis (HRR¼ 0.58, 95% CI¼ 0.42 to 0.79 for 4 vs 1 FTP,
Ptrend¼ .0001), but not in the prospective cohort (HRp¼ 1.68, 95%
CI¼ 0.83 to 3.39 for 4 vs 1 FTP, Ptrend¼ .41 and
Pheterogeneity¼ .006) (Figure 1). Multiparity was associated with a
decreased BC risk only prior to age 40 years (HRR¼ 0.29, 95%
CI¼ 0.16 to 0.52 for 4 vs 1 FTP) (Table 4).
We observed an increase in risk with increasing age at first
FTP in the retrospective analysis (Ptrend¼ .0003). There was
some suggestion of a similar trend in the prospective cohort
(Ptrend¼ .12; HRp¼ 1.95, 95% CI¼ 0.95 to 3.98 for a first FTP at age
30 years vs <20 years). Recent pregnancy was associated with
BC risk (5 years relative to nulliparous; HRR¼ 1.36, 95%
CI¼ 1.03 to 1.78; HRp¼ 1.27, 95% CI¼ 0.57 to 2.86; HRc¼ 1.37, 95%
CI¼ 1.06 to 1.78). Increasing duration of breastfeeding was asso-
ciated with decreased BC risk in the retrospective analysis
(Ptrend¼ .002), but not in the prospective cohort (Ptrend¼ .59). Any
pregnancy, including IP, was associated with BC risk but only in
the retrospective cohort (Table 4).
We performed sensitivity analyses that further adjusted for
age at menarche, oral contraceptive use, and family history of
BC or excluding in situ BC. The estimates were very similar to
those in the main analysis (Supplementary Tables 1–3, available
online). Analysis based on the pseudo-incidence retrospective
cohort also gave very similar estimates to those based on the
entire retrospective cohort (Supplementary Table 4, available
online).
Discussion
Using data from the largest international cohort study of BRCA1
and BRCA2 mutation carriers to date, we found that overall par-
ity was not associated with BC risk for BRCA1 mutation carriers
but was associated with BC risk for BRCA2 mutation carriers.
Nulliparous and multiparous BRCA1 mutation carriers had
lower BC risk compared with uniparous women. Longer dura-
tion of breastfeeding also was associated with a reduced risk for
BRCA1 mutation carriers. There was some suggestion that uni-
parous women who subsequently breastfed may have a de-
crease in BC risk compared with those that did not. for BRCA2
mutation carriers, multiparity reduced risk, particularly prior to
age 40 years, and late age at first FTP was associated with in-
creased risk.
Table 2. (continued)
Characteristic
Women with breast cancer Unaffected women
Retrospective Prospective Retrospective Prospective
(n¼ 1560) (n¼ 157) (n¼ 1965) (n¼ 1453)
No. (%) or mean (SD) No. (%) or mean (SD) No. (%) or mean (SD) No. (%) or mean (SD)
Age at menarche, y
<12 238 (15.3) 29 (18.5) 337 (17.2) 237 (16.3)
12 365 (23.4) 40 (25.5) 503 (25.6) 353 (24.3)
13 404 (25.9) 37 (23.6) 454 (23.1) 377 (25.9)
14 274 (17.6) 24 (15.3) 336 (17.1) 246 (16.9)
15 247 (15.8) 27 (17.2) 303 (15.4) 214 (14.7)
Age missing 31 (2.0) 0 30 (1.5) 24 (1.7)
Never had menstrual period 1 (0.1) 0 2 (0.1) 2 (0.1)
*Others included the following studies (total number): Medical University of Vienna (MUV) (100), Modifier Study of Quantitative Effects on Disease (MODSQUAD) (80),
German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) (105), Lund-BRCA (58), Odense University Hospital (OUH) (62), Hospital Clinico San Carlos
(HCSC) (65), INterdisciplinary HEalth Research Internal Team BReast CAncer susceptibility (INHERIT) (74), National Institute of Oncology (NIO) (31), International
Hereditary Cancer Center (IHCC) (0), Stockholm-BRCA (13), The Spanish National Cancer Center (CNIO) (44), Milan Italy (12), Hospital Clinico San Carlos (10). EMBRACE
¼ Epidemiological Study of Familial Breast Cancer; GENEPSO ¼ Gene Etude Prospective Sein Ovaire; HEBON ¼ Hereditary Breast and Ovarian cancer study Netherlands;
kConFab ¼ Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; BCFR ¼ Breast Cancer Family Registry.
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Table 3. Retrospective, prospective, and combined analyses for the BRCA1 mutation carriers
Characteristic
Retrospective
Ptrend*
Prospective
Ptrend*
Combined
Ptrend*HR (95% CI) HR (95% CI) HR (95% CI)
Parous (at least 1 full-term pregnancy)†
No Referent Referent Referent
Yes 0.87 (0.72 to 1.05) 1.41 (0.94 to 2.10) 0.99 (0.83 to 1.18)
No. of full-term pregnancy† (FTP)
Nulliparous (no FTP) Referent Referent Reference
1 0.98 (0.81 to 1.20) <.0001 1.69 (1.09 to 2.62) <.0001 1.11 (0.92 to 1.34) <.0001
2 0.77 (0.63 to 0.95) 1.25 (0.81 to 1.95) 0.88 (0.73 to 1.07)
3 0.68 (0.53 to 0.86) 1.15 (0.70 to 1.90) 0.77 (0.62 to 0.97)
4 0.54 (0.40 to 0.73) 0.52 (0.27 to 1.02) 0.56 (0.42 to 0.74)
1 Referent Referent
<.0001
Reference
<.00012 0.78 (0.68 to 0.91) <.0001 0.74 (0.51 to 1.08) 0.79 (0.69 to 0.91)
3 0.69 (0.58 to 0.82) 0.68 (0.44 to 1.05) 0.70 (0.59 to 0.82)
4 0.55 (0.43 to 0.70) 0.31 (0.17 to 0.57) 0.50 (0.40 to 0.63)
Nulliparous 1.02 (0.83 to 1.24) 0.59 (0.38 to 0.92) 0.90 (0.75 to 1.09)
No. of full-term pregnancy by attained age†
<40 years
1 Referent Referent
.22
Reference
<.00012 0.73 (0.61 to 0.87) <.0001 1.08 (0.61 to 1.91) 0.79 (0.66 to 0.94)
3 0.68 (0.55 to 0.85) 0.35 (0.12 to 1.09) 0.65 (0.52 to 0.82)
4 0.63 (0.45 to 0.87) 0.67 (0.20 to 2.27) 0.64 (0.46 to 0.89)
40 years
1 Referent
<.0001
Referent
<.0001
Reference
<.00012 0.82 (0.66 to 1.03) 0.61 (0.38 to 0.99) 0.78 (0.64 to 0.96)
3 0.68 (0.54 to 0.87) 0.69 (0.41 to 1.16) 0.70 (0.56 to 0.88)
4 0.52 (0.39 to 0.70) 0.24 (0.12 to 0.48) 0.46 (0.34 to 0.61)
Age at 1st full-term pregnancy, y‡
<20 Referent
.03
Referent
.95
Reference
.0620–24 0.98 (0.81 to 1.19) 0.84 (0.54 to 1.30) 0.95 (0.80 to 1.13)
25–29 0.87 (0.71 to 1.06) 0.80 (0.52 to 1.23) 0.85 (0.71 to 1.02)
30 0.82 (0.65 to 1.04) 0.95 (0.59 to 1.55) 0.86 (0.70 to 1.07)
Year since last full-term pregnancy§
0–5 Referent
.02
Referent
.002
Reference
.00026–20 1.19 (1.03 to 1.36) 0.89 (0.59 to 1.35) 1.14 (0.99 to 1.30)
21 1.48 (1.17 to 1.87) 1.12 (0.63 to 1.98) 1.44 (1.15 to 1.81)
Nulliparous 1.05 (0.86 to 1.29) 0.55 (0.33 to 0.89) 0.92 (0.76 to 1.11)
Nulliparous Referent Referent Reference
0–5 0.95 (0.78 to 1.16) .02 1.84 (1.13 to 2.99) .002 1.09 (0.90 to 1.32) .0002
6–20 1.13 (0.90 to 1.41) 1.64 (1.02 to 2.64) 1.24 (1.01 to 1.52)
21 1.41 (1.06 to 1.87) 2.06 (1.12 to 3.79) 1.57 (1.20 to 2.06)
Year since last full-term pregnancy by number of full-term pregnancy†
1 FTP, 0–5 Referent Referent Reference
2 FTP, 0–5 0.65 (0.53 to 0.80) 0.75 (0.38 to 1.47) 0.68 (0.55 to 0.84)
1 FTP, 6–20 0.94 (0.73 to 1.20) 0.96 (0.47 to 1.95) 0.95 (0.75 to 1.21)
2 FTP, 6–20 0.84 (0.67 to 1.04) 0.65 (0.33 to 1.30) 0.82 (0.66 to 1.03)
1 FTP, 21 1.55 (1.09 to 2.21) 1.22 (0.48 to 3.07) 1.55 (1.11 to 2.17)
2 FTP, 21 0.96 (0.72 to 1.30) 0.81 (0.36 to 1.84) 0.98 (0.73 to 1.31)
Breastfeeding durationk
None Referent
.0002
Referent
.28
Reference
.00031–5 mo 0.96 (0.82 to 1.12) 1.07 (0.73 to 1.56) 0.97 (0.84 to 1.11)
6–12 mo 0.81 (0.69 to 0.95) 1.04 (0.70 to 1.54) 0.84 (0.72 to 0.97)
13–24 mo 0.75 (0.61 to 0.91) 1.05 (0.68 to 1.63) 0.80 (0.67 to 0.95)
> 24 mo 0.64 (0.48 to 0.86) 0.75 (0.44 to 1.31) 0.66 (0.50 to 0.87)
No. of full-term pregnancy and breastfeeding†
Nulliparous Referent Referent Reference
1 FTP, never breastfeeding 1.15 (0.89 to 1.49) 2.01 (1.14 to 3.55) 1.33 (1.04 to 1.70)
2 FTP, never breastfeeding 0.85 (0.67 to 1.07) 1.15 (0.67 to 1.96) 0.94 (0.76 to 1.18)
1 FTP, ever breastfeeding 0.97 (0.78 to 1.19) 1.64 (1.00 to 2.70) 1.09 (0.89 to 1.33)
2 FTP, ever breastfeeding 0.73 (0.59 to 0.89) 1.22 (0.79 to 1.90) 0.84 (0.69 to 1.02)
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Previous epidemiological studies investigating modifiable
factors for BRCA1 and BRCA2 mutation carriers have had limited
power to examine gene-specific associations and have primarily
been retrospective (8,11,19). Our cohort provides the first large-
scale prospective evaluation of parity separately for BRCA1 and
BRCA2 mutation carriers. Overall, we found that increasing par-
ity beyond the first child was associated with a decrease in BC
risk for BRCA1 mutation carriers in both the retrospective and
prospective analyses. This association with multiparity in
BRCA1 mutation carriers was consistent with a meta-analysis
that reported a 17% decrease for each additional birth (11).
Curiously, however, nulliparity was associated with a reduced
risk of BC in comparison with uniparity; this association was
particularly marked in the prospective analysis.
Increasing age at FTP was associated with reduced BC risk
for BRCA1 mutation carriers but only in the retrospective analy-
sis. Moreover, the effect size was smaller than that reported in
the meta-analysis by Friebel et al. (11) (for pregnancy after age
30 years vs before 25 years, relative risk [RR]¼ 0.65, 95% CI¼ 0.42
to 0.99). The pattern of association is clearly different from that
seen in the general population, where increased age at first FTP
is associated with increased BC risk (27).
For BRCA2 mutation carriers, we observed a positive associa-
tion with overall parity in both the retrospective and prospec-
tive analyses not driven by uniparity as observed for BRCA1
mutation carriers. We also observed an increased risk of BC
with later age at first FTP, which is more consistent with the as-
sociation seen in the general population, but in contrast to the
results of the Friebel et al. (11) meta-analysis, which found no
association. We also found an association between multiparity
and a reduced risk of BC particularly for women who had four or
more pregnancies in the retrospective analysis. We also ob-
served a modest increase in risk associated with recent preg-
nancies (5 years, relative to nulliparous) in BRCA2 mutation
carriers in both retrospective and prospective analyses (36% and
27%, respectively). for BRCA1 mutation carriers, the risk was
also higher in the first five years, relative to nulliparous women,
but this was observed only in the prospective cohort. However,
there was no difference by attained age even in the prospective
analysis where women are slightly older and no evidence that
Table 3. (continued)
Characteristic
Retrospective
Ptrend*
Prospective
Ptrend*
Combined
Ptrend*HR (95% CI) HR (95% CI) HR (95% CI)
Incomplete pregnancy§ (IP)
No full-term or incomplete pregnancy Referent Referent Reference
Full-term pregnancy, no IP 0.96 (0.79 to 1.16) 1.64 (1.03 to 2.61) 1.08 (0.90 to 1.29)
Induced abortion only 1.02 (0.82 to 1.27) 1.72 (1.04 to 2.83) 1.15 (0.93 to 1.41)
Miscarriage only 0.97 (0.78 to 1.21) 1.77 (1.09 to 2.87) 1.11 (0.91 to 1.36)
Induced abortion and miscarriage 1.09 (0.77 to 1.55) 1.09 (0.40 to 2.94) 1.11 (0.80 to 1.55)
Incomplete pregnancy relative to first full-term pregnancy§
No IP Referent Referent Reference
Before first FTP or no FTP 1.05 (0.90 to 1.22) 1.02 (0.74 to 1.41) 1.04 (0.91 to 1.19)
After first FTP 1.03 (0.89 to 1.20) 1.32 (0.93 to 1.88) 1.09 (0.94 to 1.25)
*Nulliparous excluded, risk factor as continuous.
†Adjusted for bilateral oophorectomy (Yes, No), age at 1st full-term pregnancy (<30, 30þnulliparous), strata by birth year and study site.
‡Adjusted for bilateral oophorectomy, number of full-term pregnancies (0–1, 2), strata by birth year and study site.
§Adjusted for bilateral oophorectomy, number of full-term pregnancies (0–1, 2), age at 1st full-term pregnancy, strata by birth year and study site.
kAdjusted for bilateral oophorectomy, number of live births (0–1, 2), age at 1st full-term pregnancy, strata by birth year and study site.
Figure 1. Probability of developing breast cancer in the prospective cohort by parity. A) BRCA1. B) BRCA2. Circles ¼ nulliparous; plus sign, parity ¼ 1; x, parity ¼ 2; trian-
gles, parity ¼ 3; squares, parity ¼ 4 or more.
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Table 4. Retrospective, prospective, and combined analyses for the BRCA2 mutation carriers
Characteristic
Retrospective
Ptrend*
Prospective
Ptrend*
Combined
Ptrend*HR (95% CI) HR (95% CI) HR (95% CI)
Parous (at least 1 full-term pregnancy)†
No Referent Referent Referent
Yes 1.26 (0.99 to 1.62) 1.44 (0.83 to 2.49) 1.33 (1.05 to 1.69)
No. of full-term pregnancy† (FTP)
Nulliparous Referent Referent Referent
1 1.28 (0.98 to 1.67) .0001 1.08 (0.55 to 2.14) .41 1.29 (1.01 to 1.66) .005
2 1.32 (1.00 to 1.73) 1.63 (0.91 to 2.92) 1.42 (1.09 to 1.85)
3 1.04 (0.76 to 1.44) 1.72 (0.89 to 3.34) 1.22 (0.89 to 1.66)
4 0.73 (0.51 to 1.07) 1.82 (0.91 to 3.64) 0.93 (0.66 to 1.33)
1 Referent
.0001
Referent
.41
Referent
.0052 1.03 (0.83 to 1.28) 1.51 (0.85 to 2.66) 1.10 (0.90 to 1.35)
3 0.82 (0.63 to 1.06) 1.59 (0.83 to 3.04) 0.94 (0.74 to 1.20)
4 0.58 (0.42 to 0.79) 1.68 (0.83 to 3.39) 0.72 (0.54 to 0.98)
Nulliparous 0.78 (0.60 to 1.02) 0.92 (0.47 to 1.82) 0.78 (0.60 to 0.99)
No. of full-term pregnancy by attained age†
<40 years
1 Referent
<.0001
Referent
.98
Referent
.00082 0.81 (0.62 to 1.06) 2.36 (0.47 to 11.83) 0.88 (0.67 to 1.16)
3 0.79 (0.56 to 1.13) 1.25 (0.14 to 11.55) 0.81 (0.56 to 1.19)
4 0.29 (0.16 to 0.52) 1.31 (0.09 to 19.54) 0.33 (0.17 to 0.63)
40 years
1 Referent
.005
Referent
.39
Referent
.042 1.28 (0.95 to 1.73) 1.33 (0.71 to 2.48) 1.26 (0.97 to 1.65)
3 0.96 (0.69 to 1.34) 1.51 (0.77 to 2.96) 1.07 (0.79 to 1.45)
4 0.77 (0.53 to 1.12) 1.57 (0.76 to 3.25) 0.90 (0.64 to 1.26)
Age at 1st full-term pregnancy, y‡
<20 Referent
.0003
Referent
.12
Referent
<.000120–24 1.13 (0.87 to 1.47) 1.60 (0.85 to 2.98) 1.25 (0.97 to 1.60)
25–29 1.39 (1.05 to 1.84) 1.26 (0.63 to 2.51) 1.39 (1.06 to 1.83)
30 1.64 (1.20 to 2.24) 1.95 (0.95 to 3.98) 1.77 (1.30 to 2.40)
Year since last full-term pregnancy§
0–5 Referent
.57
Referent
.06
Referent
.406–20 0.97 (0.79 to 1.18) 0.82 (0.42 to 1.59) 0.96 (0.79 to 1.17)
21 0.92 (0.67 to 1.25) 0.71 (0.31 to 1.64) 0.88 (0.65 to 1.19)
Nulliparous 0.74 (0.56 to 0.97) 0.79 (0.35 to 1.77) 0.73 (0.56 to 0.94)
Nulliparous Referent Referent Referent
0–5 1.36 (1.03 to 1.78)
.57
1.27 (0.57 to 2.86) .06 1.37 (1.06 to 1.78) .40
6–20 1.31 (0.98 to 1.76) 1.04 (0.51 to 2.14) 1.32 (1.01 to 1.74)
21 1.24 (0.86 to 1.79) 0.90 (0.38 to 2.15) 1.21 (0.86 to 1.70)
Breastfeeding duration§
None Referent
.002
Referent
.59
Referent
.011–5 mo 1.00 (0.82 to 1.24) 1.14 (0.69 to 1.88) 1.05 (0.87 to 1.28)
6–12 mo 1.16 (0.93 to 1.43) 1.28 (0.77 to 2.13) 1.17 (0.96 to 1.43)
13–24 mo 0.85 (0.66 to 1.09) 0.74 (0.40 to 1.35) 0.82 (0.64 to 1.04)
> 24 mo 0.61 (0.43 to 0.86) 1.03 (0.58 to 1.81) 0.74 (0.55 to 1.00)
No. of full-term pregnancy and breastfeeding†
Nulliparous Referent Referent Referent
1 FTP, never breastfeeding 1.33 (0.91 to 1.93) 1.90 (0.77 to 4.72) 1.45 (1.02 to 2.06)
2 FTP, never breastfeeding 1.25 (0.91 to 1.72) 1.32 (0.66 to 2.65) 1.31 (0.98 to 1.77)
1 FTP, ever breastfeeding 1.33 (1.00 to 1.78) 0.79 (0.35 to 1.80) 1.27 (0.98 to 1.66)
2 FTP, ever breastfeeding 1.19 (0.90 to 1.57) 1.71 (0.97 to 3.03) 1.35 (1.03 to 1.76)
Incomplete pregnancy (IP)§
No full-term or Incomplete pregnancy Referent Referent Referent
Full-term pregnancy, no IP 1.35 (1.05 to 1.75) 0.82 (0.40 to 1.68) 1.28 (1.00 to 1.64)
Induced abortion only 1.38 (1.01 to 1.89) 0.47 (0.18 to 1.17) 1.15 (0.85 to 1.56)
Miscarriage only 1.52 (1.13 to 2.04) 0.88 (0.43 to 1.79) 1.40 (1.06 to 1.84)
Induced abortion and miscarriage 1.87 (1.19 to 2.92) 0.87 (0.35 to 2.15) 1.61 (1.07 to 2.42)
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BC risk declined by time since pregnancy, and in opposite, the
risk increased with time since last pregnancy in both the retro-
spective and prospective cohorts.
Although multiparity relative to nulliparity reduced risk in
both BRCA1 and BRCA2 mutation carriers, late age at first FTP
was only associated with increased risk for BRCA2 mutation car-
riers. The differences we observed between BRCA1 and BRCA2
mutation carriers might reflect their difference in the estrogen
receptor (ER) status distribution that has been reported by mu-
tation type (28). We did not have hormonal receptor status for
our pooled cohort, but we expect the differences we observed
reflect both hormonal status as well as age-related differences
between BRCA1 and BRCA2 mutation carriers. For example, as
we recently reported, BRCA1 and BRCA2 mutation carriers have
different BC risk distributions. For BRCA1 mutation carriers,
there is a rapid increase in BC incidence until ages 30 to
40 years, whereas the risk for BRCA2 mutation carriers contin-
ues to increase until approximately age 50 years, similar to the
distribution in the general population (1). Therefore, one can ex-
pect that risk factors may be different or act differently between
BRCA1 and BRCA2 mutation carriers because of their timing. In
particular, given the later peak in incidence for BRCA2 mutation
carriers, later age at FTP may increase risk in the short-term
similar to the transient increase from pregnancy seen in the
general population.
Retrospective analyses generally have substantially more
power but may be potentially biased for selected risk factors
given that risk factors are ascertained after diagnosis, or
might motivate study participation. Prospective cohorts have
the advantage of collecting information prior to knowing the
outcome, but often have more limited statistical power com-
pared to retrospective studies. FTPs, however, are unlikely to
have substantial information bias when collected retrospec-
tively, and for prospective analyses, the mean age at start of
follow-up has mostly passed the reproductive life period.
Similar findings between the two designs also support that
selection bias may be less of a concern as selection bias often
operates differently in retrospective and prospective studies.
We were limited, however, to addressing confounding by
only established risk factors that have been collected across
all of the studies. We formally tested for homogeneity across
the two cohorts using meta-analytic techniques, and both
random and fixed effects models suggested that the infer-
ences in both retrospective and prospective analyses were
not different from each other. Thus we were able to provide
more precise estimates by combining both cohorts. We also
investigated heterogeneity across birth cohorts
(Supplementary Figure 1, available online) and geographic
study sites and observed similar inferences.
The increased risk for uniparous BRCA1 mutation carriers
(and perhaps for BRCA2 carriers) is inconsistent with the pattern
for the general population. However, the lack of a protective ef-
fect of parity in BRCA1 mutation carriers who develop primarily
ER-negative tumor is consistent with the weaker association
with parity and age at first FTP observed for ER-negative BC in
the general population (28). It suggests that many of the key
driver events may have already occurred in adolescence, such
that the first FTP increases the risk of BC due to stimulation of
partially transformed mammary cells. This risk may be stronger
for first pregnancy for those most susceptible based on prior
exposures and then decline after FTP given increased cell differ-
entiation in the late phase of pregnancy and lactation and post-
partum gland involution (29–33), thus the lower risk for the
uniparous women who breastfeed than women who do not
may be explained by the differential rates of mammary gland
involution.
Nulliparous and multiparous BRCA1 mutation carriers have
lower BC risk compared with uniparous women. Long duration
of breastfeeding decreased risk for BRCA1 mutation carriers. For
BRCA2 mutation carriers, multiparity seems to reduce risk, al-
though this was limited to the retrospective cohort analyses,
and late age at first FTP increased risk. These findings might
help refine the BC risk estimates and make it possible to adapt
the surveillance of mutation carriers according to their repro-
ductive life history.
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Table 4. (continued)
Characteristic
Retrospective
Ptrend*
Prospective
Ptrend*
Combined
Ptrend*HR (95% CI) HR (95% CI) HR (95% CI)
Incomplete pregnancy relative to first full-term pregnancy§
No IP Referent Referent Referent
Before first FTP or no FTP 1.34 (1.10 to 1.63) 0.78 (0.50 to 1.21) 1.17 (0.97 to 1.40)
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*Nulliparous excluded, risk factor as continuous.
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